scholarly journals LsGRP1, a class II glycine‐rich protein of Lilium , confers plant resistance via mediating innate immune activation and inducing fungal programmed cell death

2020 ◽  
Vol 21 (9) ◽  
pp. 1149-1166
Author(s):  
Chia‐Hua Lin ◽  
Ying‐Chieh Pan ◽  
Nai‐Hua Ye ◽  
Yu‐Ting Shih ◽  
Fan‐Wei Liu ◽  
...  
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Plant Resistance ◽  
Immune Activation ◽  
Class Ii ◽  
Innate Immune ◽  
Innate Immune Activation ◽  
Glycine Rich Protein

scholarly journals RNA-based vaccines and innate immune activation: Not too hot and not too cold

2021 ◽  
Vol 29 (4) ◽  
pp. 1365-1366
Author(s):  
Robert Frederickson ◽  
Roland W. Herzog
Keyword(s):  
Immune Activation ◽  
Innate Immune ◽  
Innate Immune Activation

scholarly journals Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future

2017 ◽  
Vol 2017 ◽  
pp. 1-10 ◽  
Author(s):  
Ece Esin
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Checkpoint Inhibitors ◽  
Innate Immune ◽  
Small Subset ◽  
New Class ◽  
Combination Strategies ◽  
Combination Methods ◽  
Immune Editing ◽  
Cell Death Protein

In the last decade, we have gained a deeper understanding of innate immune system. The mechanism of the continuous guarding of progressive mutations happening in a single cell was discovered and the production and the recognition of tumor associated antigens by the T-cells and elimination of numerous tumors by immune-editing were further understood. The new discoveries on immune mechanisms and its relation with carcinogenesis have led to development of a new class of drugs called immunotherapeutics. T lymphocyte-associated antigen 4, programmed cell death protein 1, and programmed cell death protein ligand 1 are the classes drugs based on immunologic manipulation and are collectively known as the “checkpoint inhibitors.” Checkpoint inhibitors have shown remarkable antitumor efficacy in a broad spectrum of malignancies; however, the strongest and most durable immune responses do not last long and the more durable responses only occur in a small subset of patients. One of the solutions which have been put forth to overcome these challenges is combination strategies. Among the dual use of methods, a backbone with either PD-1 or PD-L1 antagonist drugs alongside with certain cytotoxic chemotherapies, radiation, targeted drugs, and novel checkpoint stimulators is the most promising approach and will be on stage in forthcoming years.

Differential proteomics reveals age-dependent liver oxidative costs of innate immune activation in mice

2016 ◽  
Vol 135 ◽  
pp. 181-190 ◽  
Author(s):  
Marine I. Plumel ◽  
Margaux Benhaim-Delarbre ◽  
Magali Rompais ◽  
Danièle Thiersé ◽  
Gabriele Sorci ◽  
...  
Keyword(s):  
Immune Activation ◽  
Innate Immune ◽  
Differential Proteomics ◽  
Innate Immune Activation ◽  
Age Dependent
Sign in / Sign up

Export Citation Format

Share Document